Literature DB >> 25015521

What are the risk factors for residual tumor cells after endoscopic complete resection in gastric epithelial neoplasia?

Gak Won Yun, Jie-Hyun Kim, Yong Chan Lee, Sang Kil Lee, Sung Kwan Shin, Jun Chul Park, Hyun Soo Chung, Jae Jun Park, Young Hoon Youn, Hyojin Park.   

Abstract

BACKGROUND: In early gastric cancer (EGC) and gastric adenoma, residual tumors may develop despite complete endoscopic resection (ER). To improve the chance of curative resection, we investigated the risk factors of residual tumor development in completely resected gastric epithelial neoplasia after ER.
METHODS: In total, 3,879 gastric epithelial neoplasms showing complete resection after ER were examined; 46 (1.2 %) residual tumors were found upon follow-up endoscopy. Clinicopathological characteristics were evaluated between those with and without residual tumors.
RESULTS: For gastric adenoma, high-grade dysplasia and severe intestinal metaplasia (IM) in the background mucosa were significantly associated with residual tumors. For EGC, poorly differentiated adenocarcinoma (PD), signet ring cell carcinoma (SRC), having a minimum lateral safety margin of <3 mm, and localization in the upper third of the stomach were significantly associated with residual tumors. Multivariate analysis revealed that a lateral safety margin of <3 mm (OR 13.8; p < 0.001), PD (OR 16.3; p = 0.014), and SRC (OR 9.8; p = 0.009) among EGC patients, and severe IM in the background mucosa (OR 9.0; p = 0.024) among gastric adenoma patients, were significantly associated with residual tumors.
CONCLUSIONS: For neoplasms with undifferentiated histology (PD or SRC), short-term endoscopic follow-up may help to detect residual tumors that form after complete resection via ER. For EGC, the lateral margin may be considered safe if greater than 3 mm. However, the possibility of satellite lesions should be investigated when the gastric adenoma to be resected is surrounded by severe IM.

Entities:  

Mesh:

Year:  2015        PMID: 25015521     DOI: 10.1007/s00464-014-3693-5

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  15 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

2.  Predictive factors for local recurrence after endoscopic resection for early gastric cancer: long-term clinical outcome in a single-center experience.

Authors:  Jun Chul Park; Sang Kil Lee; Ju Hee Seo; Yu Jin Kim; Hyunsoo Chung; Sung Kwan Shin; Yong Chan Lee
Journal:  Surg Endosc       Date:  2010-04-29       Impact factor: 4.584

Review 3.  Endoscopic resection of early gastric cancer.

Authors:  Takuji Gotoda
Journal:  Gastric Cancer       Date:  2007-02-23       Impact factor: 7.370

4.  Superficial flat-type early carcinoma of the stomach.

Authors:  M Mori; Y Adachi; Y Kakeji; D Korenaga; K Sugimachi; M Motooka; T Ooiwa
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

5.  Endoscopic mucosal resection for treatment of early gastric cancer.

Authors:  H Ono; H Kondo; T Gotoda; K Shirao; H Yamaguchi; D Saito; K Hosokawa; T Shimoda; S Yoshida
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

6.  Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers.

Authors:  Takuji Gotoda; Akio Yanagisawa; Mitsuru Sasako; Hiroyuki Ono; Yukihiro Nakanishi; Tadakazu Shimoda; Yo Kato
Journal:  Gastric Cancer       Date:  2000-12       Impact factor: 7.370

7.  Surgical outcome after incomplete endoscopic submucosal dissection of gastric cancer.

Authors:  H Jung; J M Bae; M G Choi; J H Noh; T S Sohn; S Kim
Journal:  Br J Surg       Date:  2010-11-04       Impact factor: 6.939

8.  Pretreatment staging of endoscopically early gastric cancer with a 15 MHz ultrasound catheter probe.

Authors:  K Akahoshi; Y Chijiwa; S Hamada; I Sasaki; H Nawata; T Kabemura; D Yasuda; H Okabe
Journal:  Gastrointest Endosc       Date:  1998-11       Impact factor: 9.427

9.  Risk factors of residual or recurrent tumor in patients with a tumor-positive resection margin after endoscopic resection of early gastric cancer.

Authors:  Hyuk Yoon; Sang Gyun Kim; Jeongmin Choi; Jong Pil Im; Joo Sung Kim; Woo Ho Kim; Hyun Chae Jung
Journal:  Surg Endosc       Date:  2012-12-18       Impact factor: 4.584

10.  Signet ring cell carcinoma of the stomach.

Authors:  Y Maehara; Y Sakaguchi; S Moriguchi; H Orita; D Korenaga; S Kohnoe; K Sugimachi
Journal:  Cancer       Date:  1992-04-01       Impact factor: 6.860

View more
  5 in total

1.  Investigation of each histological type in undifferentiated early gastric cancer and validity of diagnosis of the disease range.

Authors:  Yoshikazu Yoshifuku; Yoji Sanomura; Shiro Oka; Shinji Tanaka; Kazuaki Chayama
Journal:  Gastric Cancer       Date:  2015-11-19       Impact factor: 7.370

Review 2.  Important considerations when contemplating endoscopic resection of undifferentiated-type early gastric cancer.

Authors:  Jie-Hyun Kim
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 3.  Resection line involvement after gastric cancer treatment: handle with care.

Authors:  Paolo Morgagni; Giuliano La Barba; Eleonora Colciago; Giovanni Vittimberga; Giorgio Ercolani
Journal:  Updates Surg       Date:  2018-06-23

4.  Endoscopic Submucosal Dissection for the Treatment of Superficial Epithelial Gastric Neoplasia in a Portuguese Centre.

Authors:  Rita Seara Costa; Aníbal Ferreira; Tiago Leal; Dalila Costa; Carla Rolanda; Raquel Gonçalves
Journal:  GE Port J Gastroenterol       Date:  2018-04-11

Review 5.  Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for undifferentiated-type early gastric cancer meeting the expanded criteria: a systematic review and meta-analysis.

Authors:  Hyo-Joon Yang; Jie-Hyun Kim; Na Won Kim; Il Ju Choi
Journal:  Surg Endosc       Date:  2022-02-22       Impact factor: 3.453

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.